Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects movement. It is the second most common neurodegenerative disorder, after Alzheimer's disease. As healthcare professionals, understanding the pathophysiology, symptoms, diagnosis, and management of PD is crucial for providing optimal patient care.
PD is characterized by the degeneration of dopamine-producing neurons in the substantia nigra, a region of the brain that regulates movement. The loss of these neurons leads to a decrease in dopamine levels, resulting in motor symptoms such as tremor, rigidity, and bradykinesia. Non-motor symptoms such as depression, cognitive impairment, and autonomic dysfunction can also occur.
Diagnosis of PD is primarily based on clinical criteria. The cardinal motor symptoms are resting tremor, rigidity, bradykinesia, and postural instability. Non-motor symptoms, including depression, sleep disorders, and cognitive impairment, are increasingly recognized as significant contributors to disability. Neuroimaging can support the diagnosis but is not required.
Management of PD is primarily symptomatic. Levodopa, combined with a dopa-decarboxylase inhibitor, remains the most effective treatment for motor symptoms. Non-motor symptoms are managed based on individual patient needs. Deep brain stimulation and other surgical options can be considered in advanced cases.
Healthcare professionals play a vital role in managing PD. Early identification and management of symptoms can significantly improve the quality of life for patients. Regular monitoring for progression and complications is essential. Multidisciplinary care involving neurologists, physiotherapists, occupational therapists, and mental health professionals is often beneficial.
In conclusion, PD is a complex neurodegenerative disorder with a wide range of motor and non-motor symptoms. Understanding the disease process, clinical features, and management strategies are essential for healthcare professionals to provide comprehensive care to patients with PD.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation